Document Detail


ACE inhibition reduces infarction in normotensive but not hypertensive rats: correlation with cortical ACE activity.
MedLine Citation:
PMID:  20407464     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Angiotensin-converting enzyme (ACE) inhibition can reduce stroke risk by up to 43% in humans and reduce the associated disability, and hence understanding the mechanism of improvement is important. In animals and humans, these effects may be independent of the blood pressure-lowering effects of ACE inhibition. Normotensive (Wistar-Kyoto (WKY)) and hypertensive (spontaneously hypertensive rat (SHR)) animals were treated with the ACE inhibitors ramipril or lisinopril for 7 or 42 days before 2 hours of transient middle cerebral artery occlusion (MCAo). Blood pressure, serum ACE, and blood glucose levels were measured and stroke infarct volume was recorded 24 hours after stroke. Despite greater reductions in blood pressure, infarct size was not improved by ACE inhibition in hypertensive animals. Short-term ACE inhibition produced only a modest reduction in blood pressure, but WKY rats showed marked reductions in infarct volume. Long-term ACE inhibition had additional reductions in blood pressure; however, infarct volumes in WKY rats did not improve further but worsened. WKY rats differed from SHR in having marked cortical ACE activity that was highly sensitive to ACE inhibition. The beneficial effects of ACE inhibition on infarct volume in normotensive rats do not correlate with changes in blood pressure. However, WKY rats have ACE inhibitor-sensitive cortical ACE activity that is lacking in the SHR.
Authors:
Michelle J Porritt; Michelle Chen; Sarah S J Rewell; Rachael G Dean; Louise M Burrell; David W Howells
Related Documents :
21070734 - White-coat hypertension in the elderly. echocardiographic analysis. a substudy of the e...
3322604 - Bradykinin does not contribute to hypotension in early canine endotoxemia.
6313304 - Enalapril (mk-421), a new angiotensin-converting enzyme inhibitor. acute and chronic ef...
12131544 - Dual ace and nep inhibitor mdl-100,240 prevents and regresses severe angiotensin ii-dep...
21499494 - Current status of aggressive blood pressure control.
961894 - Responses of abdominal vascular capacitance to stimulation of splachnic nerves.
Publication Detail:
Type:  Journal Article     Date:  2010-04-21
Journal Detail:
Title:  Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism     Volume:  30     ISSN:  1559-7016     ISO Abbreviation:  J. Cereb. Blood Flow Metab.     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-08-03     Completed Date:  2010-09-07     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  8112566     Medline TA:  J Cereb Blood Flow Metab     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1520-6     Citation Subset:  IM    
Affiliation:
Department of Medicine, University of Melbourne, Austin Health, Heidelberg, Victoria, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Animals
Cerebral Cortex / drug effects,  enzymology
Hypertension / drug therapy*,  enzymology
Infarction, Middle Cerebral Artery / drug therapy*,  enzymology
Lisinopril / therapeutic use*
Male
Peptidyl-Dipeptidase A / metabolism*
Ramipril / therapeutic use*
Rats
Rats, Wistar
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 83915-83-7/Lisinopril; 87333-19-5/Ramipril; EC 3.4.15.1/Peptidyl-Dipeptidase A
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Neuroprotection by dimethyloxalylglycine following permanent and transient focal cerebral ischemia i...
Next Document:  MRI estimation of global brain oxygen consumption rate.